论文部分内容阅读
目的探讨糖尿病合并脑梗死应用双联抗血小板聚集疗法的临床意义。方法选取2015年5月~2017年2月我院收治的72例糖尿病合并脑梗死患者作为研究对象,按照随机数字表法分为对照组和观察组,各36例。对照组采取氯吡格雷单独治疗,观察组予以双联抗血小板聚集疗法,在对照组基础上联合阿司匹林。观察两组治疗前后的神经功能缺损、日常生活能力以及不良事件发生情况。结果两组治疗后的Barthel评分高于治疗前,NIHSS评分低于治疗前,差异有统计学意义(P<0.05)。观察组治疗后的Barthel评分高于对照组,NIHSS评分低于对照组,差异有统计学意义(P<0.05)。两组的不良事件发生率比较,差异无统计学意义(P>0.05)。结论糖尿病合并脑梗死采用双联抗血小板聚集疗法的临床价值较高,可有效改善神经功能、生活能力,且安全性高。
Objective To investigate the clinical significance of double antiplatelet aggregation therapy in diabetic patients with cerebral infarction. Methods Seventy-two patients with diabetes mellitus complicated with cerebral infarction admitted to our hospital from May 2015 to February 2017 were selected as study subjects and divided into control group and observation group according to random number table. The control group was treated with clopidogrel alone, the observation group was double antiplatelet aggregation therapy, combined with aspirin on the basis of the control group. The two groups were observed before and after treatment of neurological deficits, daily living ability and adverse events. Results The Barthel score of the two groups after treatment was higher than before treatment, and the NIHSS score was lower than before treatment (P <0.05). The observation group Barthel score after treatment was higher than the control group, NIHSS score was lower than the control group, the difference was statistically significant (P <0.05). There was no significant difference in the incidence of adverse events between the two groups (P> 0.05). Conclusion The clinical value of dual antiplatelet aggregation therapy in patients with diabetes mellitus complicated with cerebral infarction is high, which can effectively improve the nerve function and life ability and is safe.